Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have received an average rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports.

Biohaven Ltd. (NYSE:BHVN – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 9,440,000 shares, a decline of ...

Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...

After hours: February 21 at 6:53:05 PM EST ...